The FDA on December 17, 2025, approved RUBRACA® for adults with a deleterious BRCA mutation (BRCAm) (germline and/or somatic)-associated metastatic Castration-Resistant Prostate Cancer (mCRPC) previously treated with an Androgen Receptor-directed therapy. Patients should be selected for therapy using an FDA-approved companion diagnostic (CDx). RUBRACA® is a product of pharmaand GmbH.
Bottom Ad
Advertisement
Subscribe
